Материал: 10 Фибрилляция предсердий

243.Абдалла Аднан, Рулин В. А., Мазур Н. А. и др. Фармакокинетика

ифармакодинамика нового отечественного антиаритмического препарата аллапинина. Фармакол. и токсикол. 1988; № 5: 47–49.

244.Курбанов Р. Д., Абдуллаев ТА. Фармако-динамика и эффективность аллапинина у больных с нарушениями ритма сердца. Клин.

Мед.1988; № 10: 52–55.

245.Сыркин А. Л., Иванов Г. Г., Аксельрод А. С. и др. Прогнозирование эффективности поддерживающей антиаритмической терапии при пароксизмальной форме фибрилляции предсердий. Кардиология

исердечно-сосудистая хирургия 2010; № 4: 84–87.

246.Метелица В. И. Справочник по клинической фармакологии сер- дечно-сосудистых лекарственных средств. М.: МИА, 2005.

247.Соколов С. Ф., Голицын С, П., Малахов В. И. и др. Влияние аллапинина на функцию предсердно–желудочковой проводящей системы сердца. Кардиология 1988; № 11: 90–95.

248.Каверина Н. В., Лысковцев В. В., Сенова З. П. и др. Этацизин: фармакологические свойства и перспективы клинического применения. Кардиология 1984; № 5: 52–57.

249.Недоступ А. В., Благова О. В. Этацизин: место в лечении аритмий. Кардиология и сердечно-сосудистая хирургия 2009; № 4: 62–68.

250.Кукес В. Г., Шугушев Х. Х., Гнеушев Е. Т. И др. Фармакокинетика

ифармакодинамика нового антиаритмического препарата этацизина при приеме внутрь. Сов. медицина 1985; № 4: 81–82.

251.Лозинский Л. Г., Замотаев И. П., Керимова Р. Э. и др. Результаты лечения пароксизмальной мерцательной аритмии этацизином.

Кардиология 1989; № 7: 37–40.

252.Шугушев Х. Х., Сметнев А. С., Розенштраух Л. В. и др. Первый опыт клинического применения нового отечественного антиаритмического препарата – диэтиламинового аналога этмозина – у больных с различными нарушениями ритма сердца.

Кардиология 1982; № 5: 71–75.

253.Юрявичюс И. А., Розенштраух Л. В., Ундровинас А. И. и др. Действие нового антиаритмического препарата этмозина на силу сокращения, трансмембранный потенциал действия и быстрый входящий натриевый ток предсердной мышцы лягушки.

Кардиология 1978; 9: 118–125.

254.Suddoway L. A., Schwartz S. L., Barbey J. T., Woosley R. L. Clinical pharmacokinetics of moricizine. Am J Cardiol 1990; 65: 21D-25D; discussion 68D-71D.

255.Woosley R. L., Morganroth J, Fogoros R. N., et al. Pharmacokinetics of moricizine HCl. Am J Cardiol. 1987; 60: 35F-39F.

256.Mahler S. A., Borland R. M. Clinical development of moricizine as an antiarrhythmic agent. Am J Cardiol 1990; 65:11D-14D; discussion 68D-71D.

257.Morganroth J., Pratt C. M., Kennedy H. L., et al. Efficacy and tolerance of Ethmozine (moricizine HCl) in placebo-controlled trials. Am J Cardiol 1987; 60: 48F-51F.

258.Попова Е. П., Лысковцев В. В., Каверина Н. В. Электрофизиоло гические эффекты и антиаритмическое действие препаратов I класса этмозина и этацизина в условиях активации парасимпатической нервной системы. Вестник аритмологии 2004; 37: 57–61.

259.Шугушев Х. Х., Малахов В. И., Шестакова Н. В. Первые результаты клинического использования этацизина у пациентов с пароксизмальной фибрилляцией предсердий. Тер. Арх. 1986; 58 (3): 49–52.

260.Connolly S. J. Evidence-based analysis of amiodarone efficacy and safety. Circula-tion 1999; 100: 2025–2034.

261.Kirchhof P., Franz M. R., Bardai A., Wilde A. M. Giant T–U waves precede torsades de pointes in long QT syndrome. A systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. JACC 2009; 54: 143–149.

262.Kaab S., Hinterseer M., Nabauer M., Steinbeck G. Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome – a case-control pilot study using i. v. sotalol. Eur Heart J 2003; 24: 649–657.

263.Le Heuzey J., De Ferrari G. M., Radzik D., et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients

with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21: 597–605.

264. Kober L., Torp-Pedersen C., McMurray J.J., et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678–2687.

265. Karlson B. W., Torstensson I., Abjorn C., et al. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 1988; 9: 284–290.

266.Crijns H. J., Gosselink A. T., Lie K. I. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. Cardiovasc Drugs Ther 1996; 10: 145–152.

267.Канорский С. Г., Скибицкий В. В., Федоров А. В. Клиническая эффективность и возможный риск противорецидивной терапии пароксизмальной фибрилляции предсердий: необходимость учета вегетативных влияний на сердце. Вестник аритмологии

1998; № 7: 20–26.

268.Bardy G. H., Lee K. L., Mark D. B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225–237.

269.Piccini J. P., Hasselblad V., Peterson E. D., et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. JACC 2009; 54: 1089–1095.

270.Singh D., Cingolani E., Diamon G. A., Kaul S. Dronedarone for atrial fibrillation: have we expanded the antiarrhythmic armamentarium. JACC 2010; 55: 1569–1576.

271.Freemantle N., Mitchell S., Orme M., et al. Morbidity and mortality associated with anti-arrhythmic drugs in atrial fibrillation: a systematic review and mixed treatment meta-analysis (abstract). Circulation 2009; 120: S691–S692.

272.Echt D. S., Liebson P. R., Mitchell L. B., et al., Investigators and the CAST investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781–788.

273.Roy D., Talajic M., Dorian P., et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342: 913–920.

274.Singh S. N., Fletcher R. D., Fisher S. G., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Anti-arrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333: 77–82.

275.Van Gelder I. C., Crijns H. J., Van Gilst W. H., et al. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989; 64: 1317–1321.

276.Singh B. N., Connolly S. J., Crijns H. J.G.M., et al. Dronedarone for

maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357: 987–999.

277. Zimetbaum P. J. Dronedarone for atrial fibrillation – an odyssey.

N. Engl.J. Med. 2009; 360: 1811–1813.

278.Nieuwlaat R., Hohnloser S. H., Connolly S. J. Effects of dronedarone in patients with permanent atrial fibrillation during the ATHENA study [abstract]. Eur Heart J 2011; 32: 618.

279.Joghetaei N., Weirich G., Huber W., Buchler P., Estner H. Acute liver failure associated with dronedarone. Circ Arrhythm Electrophisiol 2011; 4: 592–593.

280.Skanes A. C., Healey J. S., Cairns J. A., et al., and the Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control. Can J Cardiol 2012; 28: 125–136.

281.Shah A. N., Mittal S., Sichrovsky T. C., et al. Long-term outcome following successful pulmonary vein isolation: pattern and prediction of very late recurrence. J Cardiovasc Electrophysiol 2008; 19: 661–667.

282.Calkins H., Reynolds M. R., Spector P., et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009; 2: 349–361.

283.Noheria A., Kumar A., Wylie J. V. Jr, Josephson M. E. Catheter ablation vs anti-arrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med 2008; 168: 581–586.

284.Jais P., Cauchemez B., Macle L., et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008; 118: 2498–2505.

285.Wazni O. M., Marrouche N. F., Martin D. O., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293: 2634–2640.

286.Pappone C., Augello G., Sala S., et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. JACC 2006; 48: 2340–2347.

287.Бокерия Л. А., Ревишвили А. Ш., Оганов Р. Г. и др. Клинические рекомендации (ВНОА, ВНОК, АССХ) по проведению электрофизиологических исследований, катетерной аблации и применения имплантируемых антиаритмических устройств. Москва, 2009, “Асконлайн”, 237–303.

288.Cosedis Nielsen J., Johannessen A., Raatikainen P., et al. A randomized comparison of radiofrequency ablation and anti-arrhythmia drug therapy as first line treatment in paroxysmal atrial fibrillation. N Engl J Med 2012: in press.

289.Wazni O. M., Marrouche N. F., Martin D. O., et al. Radiofre-quency ablation vs antiarrhythmic drugs as firstline treatment of symptomatic atrial fibrillation: A randomized trial. JAMA 2005; 293: 2634–2640.

290.Boersma L. V., Castella M., van Boven W., et al. Atrial fibrillation catheter ablation vs. surgical ablation treatment (FAST): a 2-center randomized clinical trial. Circulation 2012; 125: 23–30.

291.Pison L., La Meir M., van Opstal J., et al. Hybrid thoraco-scopic surgical and transvenous catheter ablation of atrial fibrillation. J Am Coll Cardiol 2012; 60: 54–61.

292.Weerasooriya R., Khairy P., Litalien J., et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? JACCl 2011; 57: 160–166.

293.Ouyang F., Tilz R., Chun J., et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 2010;122: 2368–2377.

294.Tzou W. S., Marchlinski F. E., Zado E. S., et al. Long-term outcome after successful catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 237–242.

295.Arya A., Hindricks G., Sommer P., et al. Long-term results and the predictors of outcome of catheter ablation of atrial fibrillation using steerable sheath catheter navigation after single procedure in 674 patients. Europace 2010; 12: 173–180.

296.Oral H., Knight B. P., Ozaydin M., et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. JACC 2002; 40: 100–104.

297.Lellouche N., Jaıs P., Nault I., et al. Early recurrences after atrial fibrillation ablation: prognostic value and effect of early reablation. J Cardiovasc Electrophysiol 2008; 19: 599–605.

298.Pokushalov E., Romanov A., Corbucci G., et al. Does atrial fibrillation burden measured by continuous monitoring during the blanking period predict the response to ablation at 12-month follow-up? Heart Rhythm. Published online ahead of print 23 March 2012. doi.org/10.1016/j.hrthm.2012.03.047.

299.Medi C., Sparks P. B., Morton J. B., et al. Pulmonary vein antral isolation for paroxysmal atrial fibrillation: results from long-term follow-up. J Cardiovasc Electrophysiol 2011;22: 137–141.

300.Pappone C., Vicedomini G., Augello G., et al. Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: the APAF study. Circ Arrhythm Electrophysiol 2011; 4: 808–814.

301.Tanner H., Makowski K., Roten L., et al. Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors. Europace 2011; 13: 646–653.

302.Wann L. S., Curtis A. B., January C. T., et al.; ACCF/AHA Task Force Members. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a

report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 104–123.

303.Calkins H., Kuck K. H., Cappato R., et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012; 14: 528–606.

304.Wazni O., Wilkoff B., Saliba W. Catheter ablation for atrial fibrillation. N Engl J Med 2011; 365: 2296–2304.

305.Lee G., Sparks P. B., Morton J. B., et al. Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center. J Cardiovasc Electrophysiol 2011; 22: 163–168.

306.Arbelo E., Brugada J., Hindricks G., et al.; on behalf of the Atrial Fibrillation Ablation Pilot Study Investigators. ESC-EURObservational research programme: the atrial fibrillation ablation pilot study, conducted by the European Heart Rhythm Association. Europace 2012; 14:1094–1103.

307.Hoyt H., Bhonsale A., Chilukuri K., et al. Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors. Heart Rhythm 2011;8:1869–1874.

308.Cappato R., Calkins H., Chen S. A., et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 32–38.

309.Shah R. U., Freeman J. V., Shilane D., et al. Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. JACC 2012;59:143–149.

310.Herrera Siklody C., Deneke T., Hocini M., et al. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study. JACC 2011;58: 681–688.

311.Di Biase L., Burkhardt J. D., Mohanty P., et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 2010; 121: 2550–2556.

312.Haeusler K. G., Kirchhof P., Endres M. Left atrial catheter ablation and ischemic stroke. Stroke 2012; 43: 265–270.

313.Gaita F., Leclercq J. F., Schumacher B., et al. Incidence of silent

cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon. J Cardiovasc Electrophysiol 2011; 22: 961–968.

314.Kirchhof P., Bax J., Blomstrom-Lundquist C., et al. Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled “research perspectives in atrial fibrillation”. Euro-pace 2009;11: 860–885.

315.Van Gelder I. C., Haegeli L. M., Brandes A., et al. Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace 2011; 13: 1517–1525.

316.Schmidt M., Segerson N. M., Marschang H., et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol 2009; 32: 995–999.

317.Page S. P., Siddiqui M. S., Finlay M., et al. Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance? J Cardiovasc Electrophysiol 2011; 22: 265–270.

318.Gautam S., John R. M., Stevenson W. G., et al. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2011; 22: 248–254.

319.Gopinath D., Lewis W. R., Di Biase L., Natale A. Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: special considerations. J Cardiovasc Electrophysiol 2011; 22: 236–239.

320.Hakalahti A., Uusimaa P., Ylitalo K., Raatikainen M. J. Catheter ablation of atrial fibrillation in patients with therapeutic oral

anticoagulation treatment. Europace 2011; 13: 640–645. w i t h warfarin. Heart Rhythm 2011;8:805–808

321. Latchamsetty R., Gautam S., Bhakta D., et al. Management and outcomes of cardiac tamponade during atrial fibrillation ablation in the presence of therapeutic anticoagulation with warfarin. Heart Rhythm 2011; 8: 805–808.

322.Lakkireddy D., Reddy Y. M., Di Biase L., et al. Feasibility and safety of dabigatran vs. warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial Fibrillation results from a multicenter prospective registry. JACC 2012; 59: 1168–1174.

323.Gaita F., Riccardi R., Caponi D., et al. Linear cryoablation of the left atrium versus pulmonary vein cryoisolation in patients with permanent atrial fibrillation and valvular heart disease: correlation of electroanatomic mapping and long-term clinical results. Circulation 2005; 111: 136–142.

324.Cox J. L., Boineau J. P., Schuessler R. B., et al. Successful surgical treatment of atrial fibrillation. Review and clinical update. JAMA 1991; 266: 1976–1980.

325.Kirchhof P., Lip G. Y., Van Gelder I. C., et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options–a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2012;14:8–27.

326.Van Gelder I. C., Haegeli L. M., Brandes A., et al. Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace 2011; 13: 1517–1525.

327.Ngaage D. L., Schaff H. V., Mullany C. J., et al. Influence of preoperative atrial fibrillation on late results of mitral repair: is concomitant ablation justified? Ann Thorac Surg 2007; 84: 434–442; discussion 442–443.

328.Gaita F., Riccardi R., Gallotti R. Surgical approaches to atrial fibrillation. Card Electrophysiol Rev 2002; 6: 401–405.

329.Piccini J. P., Lopes R. D., Kong M. H., et al. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol 2009; 2: 626–633.

330.Nair G. M., Nery P. B., Diwakaramenon S., et al. A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2009; 20: 138–144.

331.Oral H., Scharf C., Chugh A., et al. Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation 2003; 108: 2355–2360.

332.Pappone C., Rosanio S., Oreto G., et al. Circumferential radiofrequency ablation of pulmonary vein ostia: a new anatomic approach for curing atrial fibrillation. Circulation 2000; 102: 2619–2628.

333.Pappone C., Rosanio S., Augello G., et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. JACC 2003; 42: 185–197.

334.Reynolds M. R., Zimetbaum P., Josephson M. E., et al. Costeffectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol 2009; 2: 362–369.

335.Stabile G., Bertaglia E., Senatore G., et al. Catheter ablation tre3tment in patients with drug-refractory atrial fibrillation: a prospective, multicentre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006; 27: 216–221.

336.Calo L., Lamberti F., Loricchio M. L., et al. Left atrial ablation versus biatrial ablation for persistent and permanent atrial fibrillation: a prospective and randomized study. J Am Coll Cardiol 2006; 47: 2504–2512.

337.Chen M. S., Marrouche N. F., Khaykin Y., et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with

impaired systolic function. J Am Coll Cardiol 2004; 43: 1004–1009. 338. Gentlesk P. J., Sauer W. H., Gerstenfeld E. P., et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J

Cardiovasc Electrophysiol 2007; 18: 9–14.

342.Hsu L. F., Jais P., Sanders P., et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004; 351: 2373–2383.

343.Khan M. N., Jais P., Cummings J., et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008; 359: 1778–1785.

344.Lang C. C., Santinelli V., Augello G., et al. Transcatheter radiofrequency ablation of atrial fibrillation in patients with mitral valve prostheses and enlarged atria: safety, feasibility, and efficacy. JACC 2005; 45: 868–872.

345.Oral H., Pappone C., Chugh A., et al. Circumferential pulmonaryvein ablation for chronic atrial fibrillation. N Engl J Med 2006; 354: 934–941.

346.Takahashi Y., O’Neill M.D., Hocini M., et al. Effects of stepwise ablation of chronic atrial fibrillation on atrial electrical and mechanical properties. JACC 2007; 49: 1306–1314.

347.Tondo C., Mantica M., Russo G., et al. Pulmonary vein vestibule ablation for the control of atrial fibrillation in patients with impaired left ventricular function. Pacing Clin Electrophysiol 2006; 29: 962– 970.

348.Calkins H., Brugada J., Packer D. L., et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. a report of the Heart Rhythm Society (HRS) Task Force

on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007; 4: 816–861.

349. Al-Khatib S.M., Calkins H., Eloff B. C., et al. Planning the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a Collaborative PanStakeholder Critical Path Registry Model: a Cardiac Safety Research Consortium “Incubator” Think Tank. Am Heart J 2010; 159: 17–24.

350.Calkins H., Reynolds M. R., Spector P., et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofre-quency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009; 2: 349–361.

351.Haıssaguerre M., Jaıs P., Shah D. C., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659–666.

352.Leong-Sit P., Roux J. F., Zado E., et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. Circ Arrhythm Electrophysiol 2011; 4: 11–14.

353.Savelieva I., Camm A. J. Is there any hope for angiotensinconverting enzyme inhibitors in atrial fibrillation? Am Heart J 2007; 154: 403–406.

354.Savelieva I., Kakouros N., Kourliouros A., Camm A. J. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology Guidelines. Part I: primary prevention. Europace 2011; 13: 308–328.

355.Savelieva I., Kakouros N., Kourliouros A., Camm A. J. Upstream therapies for management of atrial fibrillation: review of clinical

evidence and implications for European Society of Cardiology Guidelines. Part II: secondary prevention. Euro-pace 2011; 13: 610–625.

356. Goette A., Schon N., Kirchhof P., et al. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial. Circ Arrhythm Electrophysiol 2012; 5: 43–51.

357.Yamashita T., Inoue H., Okumura K., et al.; J-RHYTHM II Investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine

calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011;

13:473–479.

358.Bianconi L., Calo L., Mennuni M., et al. n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study. Europace 2011; 13: 174–181.

359.Kowey P. R., Reiffel J. A., Ellenbogen K. A., et al. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA 2010;304: 2363–2372.

360.Goette A., Staack T., Rocken C., et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669–1677.

361.Schneider M. P., Hua T. A., Bohm M., et al. Prevention of atrial fibrillation by renin–angiotensin system inhibition a meta-analysis. JACC 2010; 55: 2299–2307.

362.Healey J. S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. JACC 2005; 45: 1832–1839.

363.Jibrini M. B., Molnar J., Arora R. R. Prevention of atrial fibrillation by way of abrogation of the renin–angiotensin system: a systematic review and meta-analysis. Am J Ther 2008; 15: 36–43.

364.Anand K., Mooss A. N., Hee T. T., Mohiuddin S. M. Meta-analysis: inhibition of renin– angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006; 152: 217–222.

365.Ducharme A., Swedberg K., Pfeffer M. A., et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 151: 985–991.

366.Wachtell K., Lehto M., Gerdts E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. JACC 2005; 45: 712–719.

367.Schmieder R. E., Kjeldsen S. E., Julius S., et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008; 26: 403–411.

368.Madrid A. H., Bueno M. G., Rebollo J. M., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;

106:331–336.

369.Ueng K. C., Tsai T. P., Yu W. C., et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of longstanding persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090–2098.

370.Tveit A., Seljeflot I., Grundvold I., et al. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol 2007; 99: 1544–1548.

371.Belluzzi F., Sernesi L., Preti P., et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009; 53: 24–29.

372.Disertori M., Latini R., Barlera S., et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606–1617.

373.Savelieva I., Camm A. J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med 2008;

5:30–41.

374.Savelieva I., Kourliouros A., Camm J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch Pharmacol 2010; 381: 1–13.

375.Santangeli P., Ferrante G., Pelargonio G., et al. Usefulness of statins in preventing atrial fibrillation in patients with permanent pacemaker: a systematic review. Europace 2010; 12: 649–654.

376.Patti G., Chello M., Candura D., et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing

cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114: 1455–1461.

377.Liakopoulos O. J., Choi Y. H., Kuhn E. W., et al. Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg 2009; 138: 678–686 e1.

378.Almroth H., Hoglund N., Boman K., et al. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebocontrolled multicentre study. Eur Heart J 2009; 30: 827–833.

379.Fauchier L., Pierre B., de Labriolle A., et al. Antiarrhythmic effect of statin therapy and atrial fibrillation: a meta-analysis of randomized controlled trials. JACC 2008; 51: 828–835.

380.Liu T., Li L., Korantzopoulos P., et al. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008; 126: 160–170.

381.Saravanan P., Bridgewater B., West A. L., et al. Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. Circ Arrhythm Electrophysiol 2009; 3: 46–53.

382.Heidarsdottir R., Arnar D. O., Skuladottir G. V., et al. Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery? Europace 2010; 12: 356–363.

383.Bertini M., Borleffs J. W., Delgado V., et al. Prediction of atrial fibrillation in patients with implantable cardioverter-defibrillator and heart failure. Eur J Heart Fail 2010; in press.

384.Fauchier L., Grimard C., Pierre B., et al. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol 2009; 103: 248–254.

385.Nasr I. A., Bouzamondo A., Hulot J. S., et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a metaanalysis. Eur Heart J 2007; 28: 457–462.

386.Khand A. U., Rankin A. C., Martin W., et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? JACC 2003; 42: 1944–1951.

387. Farshi R., Kistner D., Sarma J. S., et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. JACC 1999; 33: 304–310.

388.Kumar A. Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. South Med J 1996; 89: 779–785.

389.Gasparini M., Regoli F., Galimberti P., et al. Cardiac resynchronization therapy in heart failure patients with atrial fibrillation. Europace 2009; 11, Suppl 5: v82–v86.

390.Deedwania P. C., Singh B. N., Ellenbogen K., et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98: 2574–2579.

391.Shelton R. J., Clark A. L., Goode K., et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 2009; 95: 924–930.

392.Eliahou H. E., Silverberg D. S., Reisin E., et al. Propranolol for the treatment of hypertension in pregnancy. Br J Obstet Gynaecol 1978; 85: 431–436.

393.Aizer A., Gaziano J. M., Cook N. R., et al. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol 2009; 103: 1572–1577.

394.Mozaffarian D., Furberg C. D., Psaty B. M., Siscovick D. Physical activity and inci-dence of atrial fibrillation in older adults: the cardiovascular health study. Circulation 2008; 118: 800–807.

395.Mont L., Sambola A., Brugada J., et al. Long-lasting sport practice and lone atrial fibrillation. Eur Heart J 2002; 23: 477–482.

396.Heidbuchel H., Anne W., Willems R., et al. Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter. Int J Cardiol 2006; 107: 67–72.

397.Heidbuchel H., Panhuyzen-Goedkoop N., Corrado D., et al. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part I: supraventricular arrhythmias and pacemakers. Eur J Cardiovasc Prev Rehabil 2006; 13: 475–484.

398.Calvo N., Mont L., Tamborero D., et al. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace 2010; 12: 30–36.

399.Wyse D. G. Pharmacotherapy for rhythm management in elderly patients with atrial fibrillation. J Interv Card Electrophysiol 2009; 25: 25–29.

400.Bates S. M., Greer I. A., Pabinger I., et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 844S–886S.

401.Crystal E., Garfinkle M. S., Connolly S. S., et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2004; 4: CD003611.

402.Burgess D. C., Kilborn M. J., Keech A. C. Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. Eur Heart J 2006; 27: 2846–2857.

403.Bagshaw S. M., Galbraith P. D., Mitchell L. B., et al. Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. Ann Thorac Surg 2006; 82: 1927–1937.

404.Patel A. A., White C. M., Gillespie E. L., et al. Safety of amiodarone in the prevention of postoperative atrial fibrillation: a meta-analysis. Am J Health Syst Pharm 2006; 63: 829–837.

405.Buckley M. S., Nolan P. E. Jr, Slack M. K., et al. Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation. Pharmacotherapy 2007; 27: 360–368.

406.Miller S., Crystal E., Garfinkle M., et al. Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis. Heart 2005; 91: 618–623.

407.Ho K. M., Tan J. A. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose–response meta-analysis. Circulation 2009; 119: 1853–1866.

408.Daoud E. G., Snow R., Hummel J. D., et al. Temporary atrial epicardial pacing as prophylaxis against atrial fibrillation after heart surgery: a meta-analysis. J Cardiovasc Electrophysiol 2003;

14:127–132.

409.Dunning J., Treasure T., Versteegh M., Nashef S. A. Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg 2006; 30: 852–872.

410.Daoud E. G. Management of atrial fibrillation in the post-cardiac surgery setting. Cardiol Clin 2004; 22: 159–166.

411.Mathew J. P., Fontes M. L., Tudor I. C., et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291: 1720–1729.

412.Wellens H. J. Should catheter ablation be performed in asymptomatic patients with Wolff–Parkinson–White syndrome? When to perform catheter ablation in asymptomatic patients with a Wolff–Parkinson– White electrocardiogram. Circulation 2005; 112: 2201–2297; discussion 2216.

413.Pappone C., Santinelli V., Manguso F., et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff–Parkinson–White syndrome. N Engl J Med 2003; 349: 1803– 1811.

414.Chen M. S., McCarthy P.M., Lever H. M., et al. Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004; 93: 373–375.

415.Maron B. J., Olivotto I., Bellone P., Conte et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. JACC 2002;

39:301–307.

416.Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397–402.

417.Lip GY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 2010;123:785–789.

418.Heidbuchel H, Verhamme P , Alings M , et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 15 , 625–651 doi:10.1093/europace/eut083.